Format

Send to

Choose Destination
See comment in PubMed Commons below
Autoimmun Rev. 2007 Jan;6(3):126-30. Epub 2006 Sep 20.

What is after cytokine-blocking therapy, a novel therapeutic target--synovial Epstein-Barr virus for rheumatoid arthritis.

Author information

1
Department of Rheumatology and Hematology, Nihon University Nerima Hikarigaoka Hospital, 2-11-1 Hikarigaoka Nerima-ku, Tokyo, Japan. sswd98@med.nihon-u.ac.jp <sswd98@med.nihon-u.ac.jp>

Abstract

There has been significant progress in cytokine-blocking therapy for treatment of rheumatoid arthritis (RA) However, inhibition of cytokines involved in immune defense raises severe side effects. The cost of cytokine-blocking treatment is another major issue. Why are levels of inflammatory cytokines increased in RA patients? We have a large amount of circumstantial and direct evidence for the presence of Epstein-Barr virus (EBV) in RA synovial cells. Here, we provide an overview of the implications for novel approaches to therapy for RA patients, based on the most recent available evidences of anti-viral agents.

PMID:
17289546
DOI:
10.1016/j.autrev.2006.08.014
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center